Search

everythinglearnresearchcommunity

for

Search:↓

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

Higher androgen levels might make COVID-19 worse, especially in men.

Testosterone may influence COVID-19 severity and outcomes.

Women with high androgen levels may have more severe COVID-19 symptoms.

Testosterone's effects on COVID-19 are unclear and need more research.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

COVID-19 may cause temporary hair loss in some people.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Anti-androgens might help reduce COVID-19 severity in men.

COVID-19 may harm male fertility and damage the reproductive system.

TMPRSS2 helps viruses enter cells and protects the prostate from inflammation-related cancer.

COVID-19 may cause increased and quicker hair loss compared to other infections.

COVID-19 may be linked to hair loss or worsening of hair loss in some people.

Some COVID-19 patients have different skin problems, which might be the only sign of the virus or related to other health issues.

The over-the-counter supplement DHEA could make COVID-19 worse, especially in diabetics and people with G6PD deficiency.

Hair loss link to COVID-19 severity likely due to other factors.

Cepharanthine could be a strong antiviral against COVID-19.

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

COVID-19 may affect reproductive and urinary systems, needing more research for better care.

The document suggests that more research is needed to confirm if baldness can indicate a higher risk of severe COVID-19 in men.

COVID-19 diagnosis is linked to new or worsening hair diseases, with stress from the pandemic likely contributing.

The authors suggest that scalp hair might protect against COVID-19 and call for more research on scalp health and the virus.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

Mice with a virus similar to COVID-19 had skin damage, but a special treatment helped repair it.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

Balding might help identify men at higher risk for severe COVID-19, but more research is needed.

Men have worse COVID-19 outcomes than women due to genetic and hormonal differences.